Requires medicaid and insurers to include coverage for testing of PFAS levels in blood
Summary
A10211 would require most New York health insurance policies that provide medical, major medical, or similar comprehensive coverage to cover blood testing for PFAS levels when ordered by a physician or other authorized licensed health care provider. The bill defines PFAS as perfluoroalkyl and polyfluoroalkyl substances, and it applies this mandate across individual, group, and nonprofit health coverage provisions in the insurance law.
The bill also amends the social services law to make Medicaid cover PFAS blood testing under medical assistance, but only if federal financial participation is available. If federal matching funds are not available, Medicaid would not be required to cover the service. The bill would take effect on January 1 after enactment and would apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.
Impact
The bill would expand mandated health coverage in New York by adding PFAS blood testing to the list of covered services under multiple insurance statutes, including provisions governing individual policies, group policies, and health service corporations. It would also create a corresponding Medicaid coverage requirement, subject to federal funding availability, thereby affecting insurers, Medicaid administrators, health care providers, and patients seeking testing for environmental exposure to PFAS.
Sentiment
Based on the bill text and available context, the measure appears to be presented as a public health and environmental exposure response, with no recorded committee debate or votes showing opposition or support. Its introduction and referral to the Assembly Insurance Committee suggest it is still in an early stage, and the available record does not indicate any formal controversy in committee proceedings.
Contention
The main potential point of contention is cost and coverage responsibility: insurers would be required to pay for PFAS blood testing when ordered, and Medicaid coverage would depend on federal financial participation. Another possible issue is the scope of the mandate, since the bill requires coverage for testing but does not itself address treatment, follow-up care, or broader environmental remediation. No specific opposing viewpoints are documented in the available transcripts or votes.
Requires Medicaid to cover gender-affirming care regardless of federal funding; prohibits discriminatory practices by health care entities including hospitals, certain professionals, and insurers; requires insurance coverage for services or treatments for gender dysphoria or gender incongruence.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.
Prohibits insurance companies from discriminating based on genetic predisposition including refusing to issue or renew, charging any increased rate, or restricting any length of coverage; prohibits insurers from requiring genetic testing.